Year: 2025

reAlpha (Nasdaq: AIRE) Acquires Prevu to Expand Multi-State Footprint and Offer Its Integrated Realty and Mortgage Services in Additional States

Written by Customer Service on November 25, 2025. Posted in Mergers And Acquisitions.

Acquisition adds 11 new markets to reAlpha’s realty footprint and enhances its technology-driven real estate platform DUBLIN, Ohio, Nov. 25, 2025 (GLOBE NEWSWIRE) — reAlpha Tech Corp. (Nasdaq: AIRE) (“reAlpha” or the “Company”), an AI-powered real estate technology company, today announced the acquisition of Prevu Inc. (“Prevu”), a digital homebuying platform with real estate brokerage operations across 12 states and Washington, D.C. The acquisition expands reAlpha’s licensed real estate footprint into 11 new markets and represents a step-change in the Company’s multi-service expansion, unifying realty and mortgage capabilities to support a broader national footprint. Founded and headquartered in New York, Prevu is a digital-first, rebate-oriented brokerage model with more than 1,000 completed transactions, a 5-star Google rating,...

Abercrombie & Fitch Co. Reports Third Quarter Fiscal 2025 Results

Written by Customer Service on November 25, 2025. Posted in Earnings Releases And Operating Results.

Record third quarter net sales of $1.3 billion, up 7% from last year, 12th consecutive quarter of growth Net sales growth led by Americas up 7%, EMEA up 7%, partially offset by 6% decline in APAC Brand performance led by Hollister brands growth of 16%, with Abercrombie brands down 2% Operating margin of 12.0%, with earnings per diluted share of $2.36 exceeding outlook range $100 million in shares repurchased in the quarter; Year-to-date share repurchases of $350 million, 9% of shares outstanding at beginning of the year Narrows full-year outlook to net sales growth of 6% to 7%, net income per diluted share of $10.20 to $10.50NEW ALBANY, Ohio, Nov. 25, 2025 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF) today announced results for the third quarter ended November 1, 2025. These compare to results for the third quarter...

Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update

Written by Customer Service on November 25, 2025. Posted in Earnings Releases And Operating Results.

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today reported financial results for its fourth quarter of fiscal 2025. “There are currently an estimated 7.2 million people living with Alzheimer’s disease in the U.S. and 7 million in Europe, respectively. We continue to be focused on orally, targeted upstream medicines, particularly in the context of early Alzheimer’s disease,” said Christopher U. Missling, PhD, President...

BOS Continues Record Year Performance in Q3 2025, Sales Increase 16% Year-Over-Year

Written by Customer Service on November 25, 2025. Posted in Earnings Releases And Operating Results.

Raises Full-Year 2025 Revenue and Net Income Guidance RISHON LE ZION, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (BOSC) today reported financial results for the third quarter and nine months ended September 30, 2025, demonstrating continued record-breaking performance in both revenue and profitability. Third Quarter 2025 Financial HighlightsRevenue increased 15.9% to $11.4 million, compared to $9.8 million in Q3 2024. Net income increased 17.9% to $677,000, or $0.11 per basic share, compared to $574,000, or $0.10 per basic share, in Q3 2024. EBITDA increased 29.5% to $920,000 compared to $710,000 in Q3 2024. Contracted backlog remained strong at $24 million as of September 30, 2025, compared to $24 million on June 30, 2025, and $22 million on March 31, 2025. Cash and cash equivalents reached a record...

Purpose Investments Inc. Announces Final November 2025 Distribution Rate for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund

Written by Customer Service on November 25, 2025. Posted in Dividend Reports And Estimates.

TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) — Purpose Investments Inc. announced today the final November 2025 distribution rates for Purpose High Interest Savings Fund, Purpose US Cash Fund, Purpose Cash Management Fund, and Purpose USD Cash Management Fund. The following table reflects the final distribution amounts for the month of November. Ex-distribution date is November 26, 2025.Open-End Fund TickerSymbol Final distributionper unit Record Date Payable Date DistributionFrequencyPurpose USD Cash Management Fund – ETF Units MNU.U US $ 0.3055 11/26/2025 12/02/2025 MonthlyPurpose Cash Management Fund – ETF Units MNY $ 0.2031 11/26/2025 12/02/2025 MonthlyPurpose High Interest Savings Fund – ETF Units PSA $ 0.0845 11/26/2025 12/02/2025 MonthlyPurpose US Cash Fund – ETF Units PSU.U US $ 0.2897 11/26/2025 12/02/2025 MonthlyAbout...

Clearfield Reports Fourth Quarter and Full Year 2025 Results

Written by Customer Service on November 25, 2025. Posted in Earnings Releases And Operating Results.

Fiscal 2025 Clearfield net sales from continuing operations grew 20% to $150.1 million; Gross margin improved by over 13 percentage points from 20.6% to 33.7%Fiscal 2025 Clearfield net income from continuing operations per share improved to $0.45 from a net loss per share of $(0.58) in fiscal 2024After the divestiture of Nestor Cables, Clearfield expects full year fiscal 2026 revenue from continuing operations in the range of $160 million to $170 million and EPS of $0.48 to $0.62Board of Directors increased share repurchase program authorization from $65 million to $85 millionMINNEAPOLIS, Nov. 25, 2025 (GLOBE NEWSWIRE) — Clearfield, Inc. (NASDAQ: CLFD), a leader in fiber connectivity, reported results for the fiscal fourth quarter and full year 2025. Additional commentary has been posted as a letter to Shareholders...

Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial

Written by Customer Service on November 25, 2025. Posted in Public Companies.

First patient recruited at leading Israeli site accelerating enrollment momentum across global study of CMND-100 Vancouver, Canada, Nov. 25, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that Tel Aviv Sourasky Medical Center (“TASMC”), one of Israel’s top-tier academic medical centers, has officially kicked off patient enrollment by successfully recruiting the first participant for Clearmind’s FDA-approved multinational Phase I/IIa clinical trial of CMND-100 in Alcohol Use Disorder (AUD). The recruitment of the first patient at TASMC, under the leadership of Principal Investigator...

Kraig Biocraft Laboratories Launches Significant Hiring Initiative to Support Expanded Spider Silk Production Footprint in Southeast Asia

Written by Customer Service on November 25, 2025. Posted in Public Companies.

ANN ARBOR, Mich., Nov. 25, 2025 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces the launch of a key hiring initiative at its production operations in Southeast Asia. This expansion of the Company’s production workforce is driven by rapidly increasing throughput, an expanded operational footprint, and preparations for the opening of its newest production center, now in active development. The Company is ramping up staffing to support what it expects to be a significant increase in production volumes over the coming quarters. These new team members will play a critical role in supporting the deployment of the Company’s advanced spider silk technologies and modernized sericulture systems across its...

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Written by Customer Service on November 25, 2025. Posted in Public Companies.

LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in two investor events in December. Event: Piper Sandler 37th Annual Healthcare ConferenceType: Fireside chatDate/Time: Wednesday, December 3, 2025, at 10:00 a.m. ET Event: Noble Capital Markets Virtual PresentationDate/Time: Wednesday, December 10, 2025, at 10:00 a.m. PT A link to the live and archived Piper Sandler webcast, as well as an archived link of the Noble presentation, may be accessed on the Unicycive website under the Investors section: Events and Presentations. To schedule a 1×1 meeting with management, please...

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference

Written by Customer Service on November 25, 2025. Posted in Public Companies.

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, at 2:00 p.m. ET. The live and archived fireside chat will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days. About ANIANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable...

Year: 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals